首页|期刊导航|中国病毒学|Recent progress in anti-Chikungunya virus drug discovery:Focus on the viral life cycle and direct-acting antivirals

Recent progress in anti-Chikungunya virus drug discovery:Focus on the viral life cycle and direct-acting antiviralsOA

Recent progress in anti-Chikungunya virus drug discovery:Focus on the viral life cycle and direct-acting antivirals

Chunjiao Liu;Shixiang Pan;Mingxue Gao;Yumin Zhang;Leike Zhang;Bin Lin;Xiangrui Jiang

Wuya College of Innovation,Shenyang Pharmaceutical University,Shenyang 110016,China||Shandong Laboratory of Yantai Drug Discovery,Bohai Rim Advanced Research Institute for Drug Discovery,Yantai 264117,ChinaShandong Laboratory of Yantai Drug Discovery,Bohai Rim Advanced Research Institute for Drug Discovery,Yantai 264117,China||Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,ChinaShandong Laboratory of Yantai Drug Discovery,Bohai Rim Advanced Research Institute for Drug Discovery,Yantai 264117,China||School of Pharmacy,Anhui University of Traditional Chinese Medicine,Hefei 230012,ChinaKey Laboratory of Virology and Biosafety,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan 430071,ChinaKey Laboratory of Virology and Biosafety,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan 430071,China||University of Chinese Academy of Sciences,Beijing 100049,ChinaWuya College of Innovation,Shenyang Pharmaceutical University,Shenyang 110016,ChinaShandong Laboratory of Yantai Drug Discovery,Bohai Rim Advanced Research Institute for Drug Discovery,Yantai 264117,China||Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China||University of Chinese Academy of Sciences,Beijing 100049,China

Chikungunya virus(CHIKV)AntiviralSmall molecule inhibitorsStructural proteinsNon-structural proteins

Chikungunya virus(CHIKV)AntiviralSmall molecule inhibitorsStructural proteinsNon-structural proteins

《中国病毒学》 2026 (4)

735-752,18

This work was supported by the Key R&D Program of Shandong Province,China(2025CXPT012,2024CXPT029),Shanghai Institute of Materia Medica,Chinese Academy of Sciences(SIMM0120231003),Yantai High-End Talent Introduction and Cultivation"Double-Hundred Plan"and the start-up funding(to X.J.)provided by Shandong Labora-tory of Yantai Drug Discovery,Bohai Rim Advanced Research Institute for Drug Discovery.

10.1016/j.virs.2026.07.001

评论